Article Text

PDF
Letters
CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer’s Disease Consortium (EADC)
  1. D Slats1,4,
  2. P E Spies1,4,
  3. M J C Sjögren1,
  4. P-J Visser5,6,
  5. M M Verbeek2,3,4,
  6. M G M Olde Rikkert1,4,
  7. P G Kehoe7
  1. 1
    Department of Geriatric Medicine, Radboud University Nijmegen Medical Centre, Donders Institute of Brain, Cognition and Behaviour, Nijmegen, The Netherlands
  2. 2
    Laboratory of Paediatrics and Neurology, Radboud University Nijmegen Medical Centre, Donders Institute of Brain, Cognition and Behaviour, Nijmegen, The Netherlands
  3. 3
    Department of Neurology, Radboud University Nijmegen Medical Centre, Donders Institute of Brain, Cognition and Behaviour, Nijmegen, The Netherlands
  4. 4
    Alzheimer Centre Nijmegen, Radboud University Nijmegen Medical Centre, Donders Institute of Brain, Cognition and Behaviour, Nijmegen, The Netherlands
  5. 5
    Alzheimer Centre Maastricht, Department of Psychiatry, University of Maastricht, Maastricht, The Netherlands
  6. 6
    Alzheimer Centre Amsterdam, Department of Neurology, VUMC, Amsterdam, The Netherlands
  7. 7
    Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol, UK
  1. Correspondence to Dr M Olde Rikkert, Department of Geriatric Medicine, 925, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands; M.Olde-Rikkert{at}ger.umcn.nl

Statistics from Altmetric.com

Cerebrospinal fluid (CSF) biomarker analysis for dementia diagnostics (ie, the analysis of amyloid β42, total tau and phosphorylated tau) is increasingly used in clinical practice.1 However, there is still debate among researchers and clinicians about the sensitivity and specificity of various biomarker analyses, especially when comparing dementia subtypes.2 The lack of consensus and heterogeneity for evidence on CSF biomarker use and validity is likely to have resulted in variable practices: belief in the utility of biomarker measurement has likely stimulated the use of CSF analysis in clinical practice in some places whereas elsewhere this practice probably has not been adopted at all. The extent of this variability …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.